In this article, we look at recent examples of how Zoetis and our colleagues are supporting the communities where we operate.
Companion Animals Feature Stories
The Zoetis for Shelters program provides exceptional discounts on many of the Zoetis products that shelters use most. The average shelter saves $4,592 a year. This money saved can instead go towards helping more pets find forever homes.
Karen Stasiak, Area Veterinarian for Zoetis, volunteers each year for the annual Can-AM Crown Sled Dog Race.
The U.S. Food and Drug Administration (FDA) has approved Simparica™, a once-monthly chewable flea and tick medication for dogs.
At our heart, Zoetis is about caring for animals – and some animals need a little more care than others. Adopting an animal from a shelter has many advantages.
The African Small Companion Animal Network (AFSCAN), a global initiative to advance companion animal medicine in Africa, has made great progress in its first year.
Following four years of extreme drought conditions, California's vulnerability to wildfires fires has drastically increased. In mid-September, the Valley fires of Northern California destroyed an...
Dr. Alejandro Bernal of Zoetis shares his insights on the growing importance of digital services to the success of veterinarians and livestock producers.
Zoetis recently sponsored the DOGRUN event in Argentina, which aimed to raise awareness among dog owners about the importance of regular veterinary care for their pets.
First targeted antibody therapy approved for control of clinical signs of atopic dermatitis in dogs
Dr. Catherine Knupp, executive vice president and president of Research and Development at Zoetis, shares her insights on the value of innovation to both animal and human health.
- Belgium (French)
- Belgium (Dutch)
- Costa Rica
- Czech Republic
- New Zealand
- South Africa
- South Korea
- United Kingdom
- United States
You are leaving the country website to access another site in the group.
Regulatory constraints and medical practices vary from country to country. Consequently, the information provided on the site in which you enter may not be suitable for use in your country.